Sagimet Biosciences Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Sagimet Biosciences Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Sagimet Biosciences Inc. do? Business model and key facts
Get the full picture of Sagimet Biosciences Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 16
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company that develops novel fatty acid synthase (FASN) inhibitors for diseases resulting from dysfunctional metabolic and fibrotic pathways. Its lead drug candidate, Denifanstat, is an oral, once-daily selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. The company was formerly known as 3-V Biosciences, Inc. and was incorporated in 2006. It is headquartered in San Mateo, California.
Stocks related to Sagimet Biosciences Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Sagimet Biosciences Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Sagimet Biosciences Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
